| 4 min read
Combining unified data architecture with standards-based hardware allows pharma companies to scale processes faster and more reliably.
| 4 min read
Eli Lilly’s oral orforglipron and Novo Nordisk’s higher-dose WeGovy could be approved on an extremely accelerated timeline. 
| 2 min read
The approach pairs ultrasound-induced tumor cell death with real-time antigen capture to drive both local and systemic immune responses.News
| 4 min read
A new drug may restore sexual function for men for months after just three days of dosing, offering hope for those who don’t respond to existing therapies.
| 4 min read
Novel Alzheimer’s screening tests, promising weight loss drug data, an AI model linking sleep to disease risk, and more led the news this week.
| 4 min read
By reengineering small-molecule chemistry for automation, Excelsior aims to remove a long-standing barrier to AI-driven drug discovery.
| 4 min read
The FDA’s National Priority Voucher program aims to cut standard review times from potentially years to months, raising questions about safety, access, and public health impact.
| 4 min read
FDA guidance now limits routine tissue biopsies, forcing researchers to rethink how blood biopsies can be optimized to reveal tissue biology.
| 3 min read
A physics-based urine test shows early promise in detecting bladder cancer recurrence without invasive procedures.
| 3 min read
Phase 2 trial shows that a topical drug rapidly reduces malodor, pain, and improves quality of life for patients with malignant fungating wounds.
| 4 min read
Preclinical systems such as patient-derived xenografts are providing unprecedented insight into tumor biology and helping bridge the gap between discovery and clinical translation.
| 8 min read
As nearly 90 percent of drugs fail in human trials, researchers are turning to patient-derived cells, engineered tissues, and AI to better predict human responses and reduce costly late-stage failures.
